| Year |
Citation |
Score |
| 2023 |
Thomas S, Prendergast GC. Gut-brain connections in neurodegenerative disease: immunotherapeutic targeting of Bin1 in inflammatory bowel disease and Alzheimer's disease. Frontiers in Pharmacology. 14: 1183932. PMID 37521457 DOI: 10.3389/fphar.2023.1183932 |
0.475 |
|
| 2023 |
Thomas S, Dilbarov N, Kelly J, Mercogliano G, Prendergast GC. Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis. Scientific Reports. 13: 11802. PMID 37479833 DOI: 10.1038/s41598-023-38830-2 |
0.449 |
|
| 2023 |
Muller AJ, Thomas S, Prendergast GC. A Brief Overview of Cancer Vaccines. Cancer Journal (Sudbury, Mass.). 29: 34-37. PMID 36693156 DOI: 10.1097/PPO.0000000000000640 |
0.526 |
|
| 2022 |
Thomas S, Mercogliano G, Prendergast GC. Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment. Plos One. 17: e0276910. PMID 36322599 DOI: 10.1371/journal.pone.0276910 |
0.52 |
|
| 2021 |
Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. IDO1 Signaling Through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research. PMID 33622713 DOI: 10.1158/2326-6066.CIR-20-0226 |
0.493 |
|
| 2020 |
Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop L, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. Abstract 1474: IDO1 signaling supports inflammatory neovascularization Cancer Research. 80: 1474-1474. DOI: 10.1158/1538-7445.Am2020-1474 |
0.554 |
|
| 2019 |
Thomas S, Laury-Kleintop L, Prendergast GC. Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues. Methods in Enzymology. 629: 219-233. PMID 31727242 DOI: 10.1016/Bs.Mie.2019.08.008 |
0.551 |
|
| 2019 |
Thomas S, Hoxha K, Tran A, Prendergast GC. Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease. Journal of Cellular Biochemistry. PMID 31211444 DOI: 10.1002/Jcb.29142 |
0.531 |
|
| 2018 |
Thomas S, Hoxha K, Alexander W, Gilligan J, Dilbarova R, Whittaker K, Kossenkov A, Prendergast GC, Mullin JM. Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. Journal of Cellular Biochemistry. PMID 30269357 DOI: 10.1002/Jcb.27716 |
0.577 |
|
| 2018 |
Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Frontiers in Oncology. 8: 370. PMID 30254983 DOI: 10.3389/Fonc.2018.00370 |
0.559 |
|
| 2018 |
Thomas S, Hoxha K, Kaufman A, Mullin JM, Prendergast G. Tu1742 - BIN1 Mab as a Novel Immunotherapy for the Treatment of Ulcerative Colitis Gastroenterology. 154: S-1007. DOI: 10.1016/S0016-5085(18)33368-7 |
0.508 |
|
| 2017 |
Rybakovsky E, Valenzano MC, Deis R, DiGuilio KM, Thomas S, Mullin JM. Improvement of Human-Oral-Epithelial-Barrier Function and of Tight Junctions by Micronutrients. Journal of Agricultural and Food Chemistry. 65: 10950-10958. PMID 29172516 DOI: 10.1021/Acs.Jafc.7B04203 |
0.314 |
|
| 2017 |
Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, Sela DA, Muller AJ, Mullin JM, Albert K, Gilligan JP, DiGuilio K, Dilbarova R, Alexander W, Prendergast GC. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research. PMID 28292977 DOI: 10.1158/0008-5472.Can-16-2929 |
0.558 |
|
| 2017 |
Mullin JM, Diguilio KM, Valenzano MC, Deis R, Thomas S, Zurbach EP, Abdulhaqq S, Montaner LJ. Zinc reduces epithelial barrier compromise induced by human seminal plasma. Plos One. 12: e0170306. PMID 28278250 DOI: 10.1371/Journal.Pone.0170306 |
0.304 |
|
| 2017 |
Mondal A, Sutanto-Ward E, DuHadaway JB, Bravo-Nuevo A, Thomas S, Prendergast GC, Muller AJ. Abstract 2680: A novel pro-tumorigenic role for IDO1 in inflammatory neovascularization Immunology. 77: 2680-2680. DOI: 10.1158/1538-7445.Am2017-2680 |
0.504 |
|
| 2016 |
Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. Methods in Molecular Biology (Clifton, N.J.). 1403: 755-61. PMID 27076165 DOI: 10.1007/978-1-4939-3387-7_43 |
0.542 |
|
| 2016 |
Thomas S. Development of Structure-Based Vaccines for Ehrlichiosis. Methods in Molecular Biology (Clifton, N.J.). 1403: 519-34. PMID 27076151 DOI: 10.1007/978-1-4939-3387-7_29 |
0.327 |
|
| 2016 |
Thomas S, Dilbarova R, Rappuoli R. Future Challenges for Vaccinologists. Methods in Molecular Biology (Clifton, N.J.). 1403: 41-55. PMID 27076124 DOI: 10.1007/978-1-4939-3387-7_2 |
0.325 |
|
| 2015 |
Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Digestive Diseases and Sciences. PMID 26195312 DOI: 10.1007/S10620-015-3804-8 |
0.546 |
|
| 2014 |
Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunology, Immunotherapy : Cii. 63: 721-35. PMID 24711084 DOI: 10.1007/S00262-014-1549-4 |
0.574 |
|
| 2014 |
Thomas S, DuHadaway J, Prendergast GC, Laury-Kleintop L. Specific in situ detection of murine indoleamine 2, 3-dioxygenase. Journal of Cellular Biochemistry. 115: 391-6. PMID 24123235 DOI: 10.1002/Jcb.24674 |
0.568 |
|
| 2014 |
Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. IDO in inflammatory programming and immune suppression in cancer Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. 311-346. DOI: 10.1007/978-1-4899-8056-4_11 |
0.485 |
|
| 2013 |
Thirumalapura NR, Crocquet-Valdes PA, Saito TB, Thomas S, McBride JW, Walker DH. Recombinant Ehrlichia P29 protein induces a protective immune response in a mouse model of ehrlichiosis. Vaccine. 31: 5960-7. PMID 24144475 DOI: 10.1016/J.Vaccine.2013.10.036 |
0.345 |
|
| 2013 |
Thomas S, Luxon BA. Vaccines based on structure-based design provide protection against infectious diseases. Expert Review of Vaccines. 12: 1301-11. PMID 24090172 DOI: 10.1586/14760584.2013.840092 |
0.333 |
|
| 2011 |
Thomas S, Thirumalapura NR, Crocquet-Valdes PA, Luxon BA, Walker DH. Structure-based vaccines provide protection in a mouse model of ehrlichiosis. Plos One. 6: e27981. PMID 22114733 DOI: 10.1371/Journal.Pone.0027981 |
0.335 |
|
| 2011 |
Crocquet-Valdes PA, Thirumalapura NR, Ismail N, Yu X, Saito TB, Stevenson HL, Pietzsch CA, Thomas S, Walker DH. Immunization with Ehrlichia P28 outer membrane proteins confers protection in a mouse model of ehrlichiosis. Clinical and Vaccine Immunology : Cvi. 18: 2018-25. PMID 22030371 DOI: 10.1128/Cvi.05292-11 |
0.342 |
|
| 2009 |
Thomas S, Thirumalapura N, Crossley EC, Ismail N, Walker DH. Antigenic protein modifications in Ehrlichia. Parasite Immunology. 31: 296-303. PMID 19493209 DOI: 10.1111/J.1365-3024.2009.01099.X |
0.319 |
|
| 2006 |
Li H, Nowak-Wegrzyn A, Charlop-Powers Z, Shreffler W, Chehade M, Thomas S, Roda G, Dahan S, Sperber K, Berin MC. Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial cells and its role in food allergy. Gastroenterology. 131: 47-58. PMID 16831589 DOI: 10.1053/J.Gastro.2006.03.044 |
0.328 |
|
| 2004 |
Thomas S, Preda-Pais A, Casares S, Brumeanu TD. RNA degradation precedes DNA cleavage in autoreactive CD4 T cells suppressed by calicheamicin gamma1. International Immunopharmacology. 4: 521-6. PMID 15099529 DOI: 10.1016/J.Intimp.2004.01.002 |
0.304 |
|
| 2003 |
Thomas S, Kumar R, Preda-Pais A, Casares S, Brumeanu TD. A model for antigen-specific T-cell anergy: displacement of CD4-p56(lck) signalosome from the lipid rafts by a soluble, dimeric peptide-MHC class II chimera. Journal of Immunology (Baltimore, Md. : 1950). 170: 5981-92. PMID 12794125 DOI: 10.4049/Jimmunol.170.12.5981 |
0.303 |
|
| Show low-probability matches. |